Meridian Bioscience (VIVO) Reports In-Line Q2 EPS

Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.22, in-line with the analyst estimate of $0.22. Revenue for the quarter came in at $48.2 million versus the consensus estimate of $48.6 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks